Earnings Feed
Start Free
Home/Filings/4/0000950170-24-097328
4//SEC Filing

Hamdy Ahmed MD 4

Accession 0000950170-24-097328

CIK 0001796129other
View on SEC.govCompany Profile

Filed

Aug 13, 8:00 PM ET

Accepted

Aug 14, 8:07 PM ET

Size

29.3 KB

Accession

0000950170-24-097328

Insider Transaction Report

Form 4
Period: 2024-08-12
Vincerx Pharma, Inc.VINC
Hamdy Ahmed MD
DirectorPresident and CEO10% Owner
Transactions
  • Award

    Stock Option (right to buy)

    2024-08-12+60,000→ 60,000 total
    Exercise: $0.55Exp: 2032-08-24→ Common Stock (60,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2024-08-12−60,000→ 0 total
    Exercise: $0.82Exp: 2032-11-14→ Common Stock (60,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2024-08-12−127,500→ 0 total
    Exercise: $6.26Exp: 2032-02-13→ Common Stock (127,500 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2024-08-12−60,000→ 0 total
    Exercise: $1.71Exp: 2032-08-24→ Common Stock (60,000 underlying)
  • Award

    Stock Option (right to buy)

    2024-08-12+127,500→ 127,500 total
    Exercise: $0.55Exp: 2032-02-13→ Common Stock (127,500 underlying)
  • Award

    Stock Option (right to buy)

    2024-08-12+90,000→ 90,000 total
    Exercise: $0.55Exp: 2033-02-14→ Common Stock (90,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2024-08-12−53,254→ 0 total
    Exercise: $7.38Exp: 2034-03-06→ Common Stock (53,254 underlying)
  • Award

    Stock Option (right to buy)

    2024-08-12+60,000→ 60,000 total
    Exercise: $0.55Exp: 2032-11-14→ Common Stock (60,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2024-08-12−90,000→ 0 total
    Exercise: $1.17Exp: 2033-02-14→ Common Stock (90,000 underlying)
  • Award

    Stock Option (right to buy)

    2024-08-12+53,254→ 200,000 total
    Exercise: $0.55Exp: 2034-03-06→ Common Stock (53,254 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2024-08-12−146,746→ 0 total
    Exercise: $7.38Exp: 2034-03-06→ Common Stock (146,746 underlying)
  • Award

    Stock Option (right to buy)

    2024-08-12+146,746→ 146,746 total
    Exercise: $0.55Exp: 2034-03-06→ Common Stock (146,746 underlying)
Footnotes (6)
  • [F1]On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the "Repriced Options"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the "Repricing"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors.
  • [F2]Option vests over three years, with 1/3 of the shares vesting on December 23, 2022, and 1/36th of the shares vesting monthly thereafter.
  • [F3]Option vests in twenty-four equal monthly installments starting from August 25, 2022.
  • [F4]Option vests in twenty-four equal monthly installments starting from November 15, 2022.
  • [F5]Option vests in twenty-four equal monthly installments starting from February 15, 2023.
  • [F6]One-third (1/3) vests on March 7, 2025, with the remainder vesting in twenty-four equal monthly installments thereafter.

Documents

1 file

Issuer

Vincerx Pharma, Inc.

CIK 0001796129

→
Entity typeother

Related Parties

1
  • filerCIK 0001458506

Filing Metadata

Form type
4
Filed
Aug 13, 8:00 PM ET
Accepted
Aug 14, 8:07 PM ET
Size
29.3 KB
View on SEC.gov